News & Research

Hyperbaric Oxygen Therapy has been used for the better part of two centuries. Search our  arhives below for past HBOT news and research or scroll down for the latest.

The Latest HBOT News & Research

Clinical Trial – Hyperbaric Oxygen Therapy for Renal Regeneration in Diabetic Nephropathy

Diabetes kidney disease is a leading cause for end stage renal disease in the western world.
To date no treatment that can reverse renal damage exists.

Chronic hypoxia is one of the major key insults affecting the diabetic kidney, and many of
the new treatments under study focus on it’s consequences, but no treatment can improve the
hypoxia as both increased renal perfusion and decreased renal perfusion may be associated
with it’s worsening. Hyperbaric oxygen therapy (HBOT) can improve renal hypoxia by increasing
partial pressure of dissolved (non-hemoglobin-bound) oxygen without affecting it’s demand.
HBOT also recruits tissue and peripheral progenitors and supplies the optimal environment
crucial for their proliferation and for tissue repair. Hyperbaric oxygen treatment was known
for years as an effective treatment for diabetic ulcers. Recent trials have shown great
impact on brain lesions (in diabetic and non-diabetic patients) it is now the time to
evaluate the effect of HBOT on the diabetic kidney.

Clinical Trial – Cardiac Output Changes During Hyperbaric and Isobaric Bupivacaine in Patients Undergoing Cesarean Section

Spinal block leads to the reduction of systemic vascular resistance (SVR) which may effect
the cardiac output. Ngan Kee et al. has showed that spina block with 0.5% hyperbaric
bupivacaine for Cesarean section combined with intravenous infusion norepinephrine had higher
cardiac output than those who received phenylephrine